Beta Bionics, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Beta Bionics announced FDA clearance of Mint, a patch pump with reusable/disposable architecture launching Q1 2027, targeting 1.5M+ units in 2027. Simultaneously submitted 3D Intelligence (next-gen algorithm with three selectable experiences) to FDA via 510(k), expecting U.S. commercialization by end-2026 as iLet 3D and Q1 2027 as Mint 3D. Full-year 2026 revenue guidance lowered to $121–126M (from $131–136M) due to up to $10M Q4 deferral as users await Mint launch; 37–39% pharmacy reimbursement, 58.5–59.5% gross margin maintained.
Why this rating
Mint clearance meaningfully expands addressable market (patch form factor, ~$12B TAM); Q1 2027 launch is 6 months early and signals execution. 3D Intelligence adds personalization. However, $10M Q4 2026 revenue deferral (~1.6% of guidance midpoint, ~0.16% of $632M market cap) is modest; near-term margin dilution noted. Significant for product portfolio but execution/reimbursement risks remain.
Price action (we called it positive)
before filing · preread $18.49 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.